Qureight открыла второй офис в Лондоне для масштабирования разработки ИИ-модели диагностики заболеваний легких

Qureight adds second site to accommodate growth and ongoing development of chest Foundation Model Expansion supports rapid scale-up and development of foundational AI imaging model, to improve clinical trial design across broader range of chest diseases 1 Sept 2026 Qureight has opened its new office space in London, UK. The expansion into a second site will accommodate the Company’s ongoing recruitment and platform technology development, to meet demand for its imaging CRO services across a broader range of lung and heart diseases. Qureight is supporting biopharma clients globally with an increasing number of clinical trials, including late-stage assets. The central London location in Holborn was strategically selected to support the Company’s rapid scale-up, housing many of the new members of its expanding machine learning and data scientist teams, with a focus on development of the 3D chest Foundation Model and AI imaging laboratory. The next-generation imaging platform will expand the Company’s existing suite of compartment-specific imaging computed tomography biomarkers for fibrotic lung diseases, enabling the rapid development of new chest imaging biomarkers. This forms part of the Company’s ongoing strategy to expand its market reach across key new therapeutic areas, including asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. The expansion to a second site aligns with Qureight’s mission to work with biopharma companies and healthcare organizations to improve clinical trial design and accelerate the development of novel therapeutics. This will enable the Company to rapidly scale its commercial and clinical operations to advance the integration of its AI-powered imaging analysis into clinical trials across therapeutic areas where there is high demand for advanced imaging analytics. “Empowered by our end-to-end, regulatory compliant, disease-agnostic clinical trials platform, Qureight is focused on redefining how lung and heart disease are tracked in clinical trials to accelerate the development of new therapies where there is high unmet medical need,” said Dr Muhunthan Thillai, MD PhD, Co-founder and CEO, Qureight. “Establishing our second site in the UK accommodates expansion of our world-class team of ML engineers and data scientists. The development of our Foundation Model is key to enabling us to enter new markets and solidify our position as a leading imaging company.” Want the latest science news straight to your inbox? Become a SelectScience member for free today>> Tags Frequently asked questions Show frequently asked questions Why has Qureight opened a second UK site in Holborn, London? Qureight opened the office to support recruitment, platform development, and growing demand for its imaging CRO services. The Holborn site will house expanding machine learning and data science teams working on its 3D chest Foundation Model and AI imaging laboratory. How will Qureight’s 3D chest Foundation Model support clinical trials? The next-generation imaging platform will extend Qureight’s computed tomography biomarker suite for fibrotic lung diseases and enable rapid development of new chest imaging biomarkers. Its AI-powered imaging analysis is intended to improve clinical trial design and accelerate novel therapeutic development. Which lung and heart disease markets is Qureight targeting with its imaging technology? Qureight plans to expand beyond fibrotic lung diseases into therapeutic areas including asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity. Its disease-agnostic, regulatory-compliant clinical trials platform helps biopharma companies track lung and heart diseases and evaluate therapies.